DaVita Inc.’s Stock Price Plummets to $157.42, Reflecting a Sharp 11.09% Decline

DaVita Inc. (DVA)

157.42 USD -19.64 (-11.09%) Volume: 5.04M

DaVita Inc.’s stock price is currently standing at 157.42 USD, witnessing a significant drop of -11.09% in this trading session with a trading volume of 5.04M, nevertheless, the stock maintains a positive YTD performance with a rise of +5.26%.

Latest developments on DaVita Inc.

DaVita stock took a hit today as Warren Buffett’s Berkshire Hathaway sold off some shares, cutting its stake in the company to 45%. Despite DaVita posting better-than-expected sales in Q4, the stock dropped following the stake sale. The disappointing guidance from Berkshire Hathaway added to the woes, leading to a plunge of over 10% in pre-market trading. Investors will be closely watching as DaVita’s stock continues to be volatile, with analysts predicting mixed outcomes for its future performance.

A look at DaVita Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

DaVita Inc., a company that offers healthcare services, has received mixed ratings on its long-term outlook according to Smartkarma Smart Scores. While it scored well in growth and momentum, with a rating of 4 in both categories, its value and resilience scores were lower at 2. The dividend score was the lowest at 1. This indicates that the company may have strong potential for growth and positive market momentum in the future, but investors should be cautious of its value and resilience factors.

DaVita Inc. specializes in providing kidney dialysis services for patients with chronic kidney failure on a global scale. The company’s Smartkarma Smart Scores reflect a promising outlook in terms of growth and momentum. However, its value and resilience scores are not as strong. With a balanced consideration of these factors, investors can make informed decisions about the long-term prospects of DaVita in the healthcare industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma